Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Colorcon
Express Scripts
McKinsey
Baxter

Last Updated: February 25, 2020

DrugPatentWatch Database Preview

EXEM FOAM KIT Drug Profile


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

When do Exem Foam Kit patents expire, and when can generic versions of Exem Foam Kit launch?

Exem Foam Kit is a drug marketed by Giskit and is included in one NDA. There are three patents protecting this drug.

This drug has six patent family members in six countries.

The generic ingredient in EXEM FOAM KIT is air polymer-type a. There are thirty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the air polymer-type a profile page.

US ANDA Litigation and Generic Entry Outlook for Exem Foam Kit

Exem Foam Kit will be eligible for patent challenges on November 7, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 7, 2024. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for EXEM FOAM KIT
International Patents:6
US Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: 1
DailyMed Link:EXEM FOAM KIT at DailyMed
Drug patent expirations by year for EXEM FOAM KIT
Generic Entry Opportunity Date for EXEM FOAM KIT
Generic Entry Date for EXEM FOAM KIT*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY
NDA:
Dosage:
FOAM;INTRAUTERINE

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for EXEM FOAM KIT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Giskit EXEM FOAM KIT air polymer-type a FOAM;INTRAUTERINE 212279-001 Nov 7, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Giskit EXEM FOAM KIT air polymer-type a FOAM;INTRAUTERINE 212279-001 Nov 7, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
Giskit EXEM FOAM KIT air polymer-type a FOAM;INTRAUTERINE 212279-001 Nov 7, 2019 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Medtronic
McKinsey
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.